Results 211 to 220 of about 12,336,620 (246)

A Case of Pseudo-Richter Transformation Following Zanubrutinib Discontinuation in CLL. [PDF]

open access: yesMediterr J Hematol Infect Dis
Laurenti L   +14 more
europepmc   +1 more source

At‐Home Versus in‐Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial

open access: yesMuscle &Nerve, Volume 74, Issue 3, Page 702-708, September 2026.
ABSTRACT Introduction/Aims Respiratory weakness, typically monitored as vital capacity (VC), is a central feature of amyotrophic lateral sclerosis (ALS). VC is increasingly measured remotely in participants' homes, although in‐clinic assessment remains the standard.
Eric A. Macklin   +269 more
wiley   +1 more source

Facilitation and competition between Acacia species and phosphorus‐mobilising plants in severely phosphorus‐impoverished habitats

open access: yesFunctional Ecology, Volume 40, Issue 9, Page 3001-3016, September 2026.
Read the free Plain Language Summary for this article on the Journal blog. Abstract Plants in fire‐prone severely phosphorus (P)‐impoverished environments exhibit diverse P‐acquisition strategies coordinated with root morphological traits. Fire transiently enhances plant‐available soil P, making efficient post‐fire P acquisition crucial for seedling ...
Ling‐Ling Chen   +7 more
wiley   +1 more source

Scaffold‐free three‐dimensional culture of chronic lymphocytic leukaemia preserves B–T‐cell cross‐talk and enables drug response profiling

open access: yesBritish Journal of Haematology, Volume 209, Issue 3, Page 953-963, September 2026.
Summary Chronic lymphocytic leukaemia (CLL) presents a complex biological and clinical landscape, strongly influenced by the tumour microenvironment (TME). To better capture this heterogeneity, we have developed patient‐derived lymphoma spheroids from CLL samples (CLL‐PDLS), which recapitulate the cross‐talk between malignant cells and the autologous ...
Heribert Playa‐Albinyana   +9 more
wiley   +1 more source

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

open access: yesBritish Journal of Haematology, Volume 209, Issue 3, Page 1010-1019, September 2026.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco   +21 more
wiley   +1 more source

Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eµ-TCL1 mice. [PDF]

open access: yesFront Oncol
Skupa SA   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy